equipifi Successfully Completes SOC 2 Type 2 Audit
equipifi completes SOC 2® Type 2 Audit to further its commitment to security as it partners with financial institutions to launch Buy Now, Pay Later SCOTTSDALE,... Read more.
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., Sept. 12, 2024 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept. 8, 2024, the company approved non-statutory... Read more.
Unisys to Participate in Upcoming Sidoti Small-Cap Conference
BLUE BELL, Pa., Sept. 12, 2024 /PRNewswire/ — Unisys (NYSE: UIS) will be participating virtually in the Sidoti Small-Cap Conference on September 19, 2024.... Read more.
Enhancing Visibility and Analytics for Banks and Broker-Dealers, Broadridge Announces New Communications Data-Driven Platform
CommCentral offers greater efficiency, API connectivity and insight into investor communications activity NEW YORK, Sept. 12, 2024 /PRNewswire/ — CommCentral,... Read more.
How to Play Pokemon Go without Moving? Try iWhereGo Genius iOS 18 Pokémon Go Spoofer
NEW YORK, Sept. 12, 2024 /PRNewswire/ — To all Pokémon Go fans, the thrill of playing should not be limited by mobility or busy schedules. Recognizing... Read more.
Montreal-based Dealership Group Lassos Up Ferrari of Rancho Mirage in California
MONTREAL, Sept. 12, 2024 /PRNewswire/ – Holand Automotive Group, one of Canada’s leading luxury automotive retailers and owner of Ferrari Quebec in Montreal... Read more.
Sandstorm Gold Royalties Reports Portfolio Drilling and Exploration Activity
VANCOUVER, Sept. 12, 2024 /PRNewswire/ – Sandstorm Gold Ltd. (“Sandstorm Gold Royalties”, “Sandstorm” or the “Company”)... Read more.
UL Research Institutes Launches State-of-the-Art Materials Discovery Laboratory Focused on Sustainability
EVANSTON, Ill., Sept. 12, 2024 /PRNewswire/ — Global safety science leader UL Research Institutes (ULRI) today launched a state-of-the-art materials science... Read more.
Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with Schizophrenia Results Confounded... Read more.
HotSpot Therapeutics Presents First-in-Human Phase 1 Clinical Data on its Novel CBL-B Inhibitor, HST-1011, at ESMO Congress 2024
HST-1011 showed an encouraging early clinical profile demonstrating important linkages between exposure, target engagement, pharmacodynamics and initial signs... Read more.